NAOV - NanoVibronix, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.1500
+0.1000 (+4.88%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close2.0500
Open2.0500
Bid0.0000 x 900
Ask0.0000 x 2900
Day's Range2.0500 - 2.1500
52 Week Range1.4200 - 4.2000
Volume745
Avg. Volume11,417
Market Cap9.275M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.3780
Earnings DateJun 29, 2020 - Jun 30, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    SANUWAVE Health Announces Exclusive Licensing of NanoVibronix, Inc. Surface Acoustic Wave Ultrasound Technology

    SUWANEE, GA, April 02, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV) and NanoVibronix, Inc. have announced an exclusive worldwide license agreement for NanoVibronix’s surface acoustic wave ultrasound technology in the wound care market. Under this agreement, SANUWAVE has acquired the exclusive worldwide license and sales rights for NanoVibronix’s patch-based therapeutic ultrasound technology device, WoundShield®, that facilitates tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. SANUWAVE will seek regulatory approval of WoundShield® in Europe and the United States and NanoVibronix shall maintain the sole right to manufacture the licensed products.

  • ACCESSWIRE

    NanoVibronix, Inc. to Present at the Investor Summit on December 17th in Philadelphia

    PHILADELPHIA, PA / ACCESSWIRE / December 10, 2019 / NanoVibronix, Inc. (NASDAQ:NAOV), will be presenting at this year's Investor Summit on December 17 th in Philadelphia. The Investor Summit will take ...

  • NAOV: Q2 2019 Results / Business Update
    Zacks Small Cap Research

    NAOV: Q2 2019 Results / Business Update

    By Brian Marckx, CFA NASDAQ:NAOV READ THE FULL NAOV RESEARCH REPORT NanoVibronix (NASDAQ:NAOV) turned in a solid performance in Q2 (ending June 30, 2019) on both a financial and operational perspective. Highlights on the financial side include setting record highs on total revenue, PainShield revenue and UroShield revenue, gross margin (78.7%) at the widest level for at least the last 14 quarters

  • PR Newswire

    NanoVibronix and Marathon Medical to Provide PainShield to VA Hospitals and the Department of Justice

    ELMSFORD, N.Y., Sept. 3, 2019 /PRNewswire/ -- NanoVibronix, Inc., (NAOV), a medical device company that produces the PainShield® Surface Acoustic Wave (SAW) Portable Ultra Sonic therapeutic device, announces on August 18th, 2019, PainShield, and PainShield Supplies were added to the Federal Supply Schedule through NanoVibronix' relationship with Marathon Medical, a Service Disabled Veteran Owned Small Business (SDVOSB) headquartered in Aurora, Colorado. The Veterans Health Administration (VA) has launched an Opioid Safety Initiative (OSI), designed to address the growing epidemic of opioid misuse and opioid use disorder in America.

  • ACCESSWIRE

    NanoVibronix Signs Distribution Agreement with ProTrade Systems for PainShield(R) MD

    ELMSFORD, NY / ACCESSWIRE / August 13, 2019 / NanoVibronix, Inc., (NAOV), a medical device company that produces the PainShield® surface acoustic wave (SAW) device, which utilizes the Company’s proprietary and patented low intensity, SAW (Surface Acoustic Wave) ultrasound technology, today announced that it has signed a distribution agreement with ProTrade Systems, a medical equipment distributor in the U.S. for thousands of patients, elite athletes, athletic trainers, professional teams, special military forces, orthopedic surgeons, sports medicine doctors, and physical therapists. PainShield MD is a wearable therapeutic ultrasound device, which emits low level, low frequency therapeutic ultrasound to deliver fast pain relief for nerve and facilitating soft tissue repair.

  • GlobeNewswire

    NanoVibronix Announces Closing of $3.2 Million Private Placement

    NanoVibronix, Inc., (NAOV), a medical device company that produces the PainShield® surface acoustic wave (SAW) device, which utilizes the Company’s proprietary and patented low intensity, SAW ultrasound technology, today announced that it closed a private placement transaction in which it issued and sold to existing stockholders 1.6 million Series E convertible preferred stock and 1.6 million 7-year warrants to purchase Series E convertible preferred stock at a price of $2.50 per share for gross proceeds to the Company of $3.2 million. The Series E convertible preferred shares are convertible into shares of common stock on a one-for-one basis. The Company plans to submit to stockholders for approval, within 90 days of the closing of the private placement, the issuance of the shares of common stock issuable upon conversion of the Series E preferred stock, in accordance with the rules of the Nasdaq Stock Market.

  • ACCESSWIRE

    NanoVibronix Announces Presentation of PainShield(R) to HCPCS Workgroup at CMS

    ELMSFORD, NY / ACCESSWIRE / June 19, 2019 / NanoVibronix, Inc., (NAOV), a medical device company that produces the PainShield® surface acoustic wave (SAW) device, which utilizes the Company's proprietary and patented low intensity, SAW ultrasound technology, announces that on June 12, 2019, the Company had the opportunity to present their signature product, PainShield® surface acoustic wave device, to the Healthcare Common Procedure Coding System (HCPCS) Workgroup at the Centers for Medicare & Medicaid Services (CMS) offices in Baltimore, Maryland. The HCPCS Workgroup is tasked with evaluating products, supplies, and services that are not included in the Current Procedural Terminology (CPT) codes, such as ambulance services and durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) when used outside a physician's office, as well as recommending appropriate payment by the Medicare and Medicaid payment systems.

  • GlobeNewswire

    NanoVibronix Announces Planned Launch of CBD Patch and Cream for PainShield® Designed to Amplify Therapeutic Effect

    ELMSFORD, N.Y., June 05, 2019 (GLOBE NEWSWIRE) --  NanoVibronix, Inc., (NAOV), a medical device company that produces the PainShield® surface acoustic wave (SAW) device, which utilizes the Company’s proprietary and patented low intensity, SAW ultrasound technology, today announced that it is developing a cannabidiol (CBD) patch and cream utilizing a proprietary and nanoparticle-based infusion process.  NanoVibronix intends to make the CBD patch as well as similarly formulated CBD cream available in combination with PainShield® as PainShield CBD™. NanoVibronix intends to demonstrate that coupling the infused patch and cream with PainShield® will increase absorption and may provide sustained pain relief for up to 24 hours.  The Company believes that this will be the first known ultrasound-based pain relief product available in combination with CBD, which can be used at home, and outside of a clinical setting, as an opioid-alternative.